ANAGENICS LIMITED — Director's Dealing 2017

Sep 3, 2017

==> picture [171 x 45] intentionally omitted <==

4 September 2017

Ms Stephanie Yong Senior Adviser, Listings Compliance ASX Compliance Pty Ltd 20 Bridge Street Sydney NSW 2000

Dear Stephanie

Appendix 3Y – Change of Director’s Interest Notice for Maria Halasz and David King

During our year end review, we have identified the following errors in reporting due to technical error and administrative oversight.

Ms Maria Halasz

Expired 5,000,000 unlisted options

These unlisted options expired on 15 June 2017 and were cancelled, but not reported, on 15 June 2017.

Purchase of 57,400 ordinary shares

On 12 May 2017, Maria Halasz purchased 57,400 shares on an electronic trading platform. Due to a technical error on the platform, the transaction was filled twice, with the result that her total share purchase was 2x57,400=114,800 shares. She was unaware of this and only reported the purchase of the intended number, 57,400 shares, in a 3Y at the time.

Dr David King

Expired 8,500,000 listed options

8,500,000 listed options held by Dr King expired on 23 October 2016 and were cancelled, but not reported, on 23 October 2016.

As a result of the above, Cellmid is now making the required notifications in the relevant Appendix 3Y forms attached.

Cellmid has implemented additional, regular administrative checks to ensure similar oversights does not occur in the future.

The Cellmid directors confirmed that they are fully aware and understand their obligations under Listing Rule 3.19A.

Yours faithfully

==> picture [97 x 48] intentionally omitted <==

Raymond Ting Company Secretary

CELLMID LIMITED ACN 111 304 119 ASX I CDY Suite 1802, Level 18, 15 Castlereagh Street, Sydney NSW 2000 AUSTRALIA TELEPHONE +61 2 9221 6830 FACSIMILE +61 2 9221 8535 WEB www.cellmid.com.au

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Cellmid Limited
ABN	69 111 304 119

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Ms Maria Halasz
Date of last notice	5 June 2017

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Indirect and direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.
Date of change	(a) 12 May 2017 (b) 15 June 2017
No. of securities held prior to change	Direct - 4,000,000 fully paid ordinary shares - 12,000,000 fully paid ordinary (loan) shares Indirect - 13,015,625 fully paid ordinary shares - 5,000,000 unlisted options (expiry 15/6/2017 exercise price $0.032)

• See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

Class	(a) Fully paid ordinary shares (Indirect) (b) Expired unlisted options
Number acquired	(a) 57,400
Number disposed	(b) 5,000,000
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation
No. of securities held after change	Direct - 4,000,000 fully paid ordinary shares - 12,000,000 fully paid ordinary (loan) shares Indirect - 13,073,025 fully paid ordinary shares
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy- back	(a) On market trade (b) Expired

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract Nature of interest Name of registered holder (if issued securities) Date of change No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed Interest acquired

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011

Appendix 3Y Change of Director’s Interest Notice

Interest disposed Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation Interest after change

Part 3 –[+] Closed period

art 3 –+Closed period
Were the interests in the securities or contracts detailed above traded during a+closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

• See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 3

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity Cellmid Limited ABN 69 111 304 119

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Dr David King
Date of last notice	17 October 2016

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Seistend Pty Ltd Seistend Pty Ltd
Date of change	23 October 2016
No. of securities held prior to change	24,000,000 fully paid ordinary shares 8,500,000 Listed Options (Exp. 23/10/16 ex price $0.034) 4,000,000 Unlisted Options$0.06 Exp. 19/11/18
Class	Listed Options at $0.034 Exp. 23/10/16
Number acquired
Number disposed	8,500,000 Listed Options
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation

• See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

No. of securities held after change	24,000,000 fully paid ordinary shares 4,000,000 Unlisted Options $0.06 Exp. 19/11/18
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Options expired

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

==> picture [434 x 316] intentionally omitted <==

----- Start of picture text -----

Detail of contract
Nature of interest
Name of registered holder
(if issued securities)
Date of change
No. and class of securities to which
interest related prior to change
Note: Details are only required for a contract in
relation to which the interest has changed
Interest acquired
Interest disposed
Value/Consideration
Note: If consideration is non-cash, provide details
and an estimated valuation
Interest after change
----- End of picture text -----

Part 3 –[+] Closed period

Part 3 –+Closed period
Were the interests in the securities or contracts detailed above traded during a+closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011